Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27564008 | 0.87 | MAP2K1 (0.51) | MAP2K1IDO1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6035710 | 0.86 | NUDT1 (0.48) | MAP2K1IDO1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5392808 | 0.86 | IDO1 (0.47) | MAP2K1IDO1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5680872 | 0.84 | ALDH1A1 (0.57) | MAP2K1IDO1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5677750 | 0.83 | IDO1 (0.62) | MAP2K1IDO1MEN1KMT2AKDM4E | |
| SCHEMBL6035982 | 0.82 | IDO1 (0.61) | MAP2K1IDO1MEN1KMT2AKDM4E | |
| SCHEMBL7623669 | 0.82 | IDO1 (0.48) | MAP2K1IDO1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL7887582 | 0.82 | IDO1 (0.48) | MAP2K1IDO1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6035979 | 0.81 | IDO1 (0.47) | MAP2K1IDO1PTGS2ALDH1A1RAB9A | |
| SCHEMBL6035296 | 0.81 | ALDH1A1 (0.48) | MAP2K1IDO1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169816-B2 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | claimed |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY LLC | 2006-03-09 | — | — | US | claimed |
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | claimed |
| EP-1140291-B1 | COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR | WARNER LAMBERT CO (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1140062-B1 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-04-06 | — | — | EP | claimed |
| EP-0993439-B1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2004-09-29 | — | — | EP | claimed |
| US-20040171632-A1 | Combination chemotherapy | GOWAN RICHARD CARLETON (US) | 2004-09-02 | — | — | US | claimed |
| CN-1163475-C | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | ��ʲ | 2004-08-25 | — | — | CN | claimed |
| US-6696440-B1 | ADMINISTERING MITOGEN ACTIVATED PROTEIN KINASE(MEK) INHIBITORS COMPRISING SECONDARY CARBOCYCLIC AMINES, AS ANTIASTHMATIC AGENTS | WARNER-LAMBERT COMPANY | 2004-02-24 | — | — | US | claimed |
| US-20030078428-A1 | Phenylamino benzhydroxamic acid derivatives inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer, psoriasis and restenosis; inhibit the phosphorylation of MAP kinase by MEK | BARRETT STEPHEN DOUGLAS (US) | 2003-04-24 | — | — | US | claimed |
| WO-2000037141-A9 | COMBINATION CHEMOTHERAPY | WARNER LAMBERT CO (US) | 2000-12-07 | — | — | WO | claimed |
| CN-1261877-A | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER LAMBERT CO (US) | 2000-08-02 | — | — | CN | claimed |
| WO-2000040237-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0993439-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001426-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078428-A1 | Phenylamino benzhydroxamic acid derivatives inhibit certain dual specificity kinase enzymes involved in proliferative diseases such as cancer, psoriasis and restenosis; inhibit the phosphorylation of MAP kinase by MEK | MAP2K2, MAP2K7, MAP2K1 | MAP2K1 3/4885IDO1 1090/4885PTGS2 333/4885 |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | MAP2K1 43/4885IDO1 762/4885PTGS2 694/4885 |
| US-20040171632-A1 | Combination chemotherapy | BUB1B, BUB1, PLK1 | MAP2K1 67/4885IDO1 2696/4885PTGS2 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.